Biotech Values

[stuartscott8900]

Dew,

After seeming hesitant on Ocrx due to the design of the phase 2b study,you purchase the stock.Is there something in the data released that gives you more confidence than previously.

Also interested if you have a opinion on Aerie Pharm.Starting phase 111 trials on a glaucoma drug that seemed to perform quite well in prior studies,in a large space with no approved therapy in 15+ years.Was interested in seeing a Regeneron officer on the BOD.

Thanks for all your comments.